Preparing for Long-Acting Antiretroviral Treatment
January 2021

Following a December 2019 U.S. Food and Drug Administration (FDA) approval delay due to Chemistry Manufacturing and Controls (CMC) issues, the first long-acting antiretroviral product for HIV treatment is expected to be available in the U.S. in the first quarter of 2021. Cabenuva® will be a co-packaged product containing cabotegravir and rilpivirine and is manufactured by ViiV Healthcare. Cabenuva will be delivered via monthly injections that generally will need to be administered in a clinical setting. This novel maintenance therapy option may help to improve adherence and reduce stigma for some patients, but will require pharmacy and/or clinical delivery system and administrative adjustments for clinics and providers.

This document highlights delivery system, staffing and administrative issues for clinics and clinicians to consider in preparing to provide patients access to this novel treatment modality. Following approval of Cabenuva by the FDA, please refer to the product package insert.

Clinical Considerations
• 48-week data from the Phase III ATLAS study and FLAIR study, demonstrating Cabenuva’s safety and efficacy as maintenance therapy with intramuscular dosing every four weeks, have been published.
• Patients will need to be virally suppressed on an oral regimen prior to initiation.
• A 30-day oral lead-in dose of 30 mg cabotegravir plus 25 mg Edurant (rilpivirine) will be required (two tablets once daily). Co-packaged oral cabotegravir plus rilpivirine is expected to be available via a limited distribution system.
• The Cabenuva loading dose requires two 3 mL IM injections (600 mg cabotegravir plus 900 mg rilpivirine).
• Maintenance dosing, involving two 2 mL IM injections (400 mg cabotegravir plus 600 mg rilpivirine), will be required every four weeks (+/– 1 week).
• Maintenance dosing administration every eight weeks, involving two 3 mL IM injections, is being evaluated in the ATLAS-2M clinical trial, with preliminary data reported at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2020. A supplemental New Drug Application is expected to be filed by the manufacturer following initial approval of every-four-week maintenance dosing.
• Cold-chain supply and storage (2° to 8° C) will be required. Cabenuva will need to be brought to room temperature before administration. Cabenuva is expected to be approved for gluteal intramuscular use only. Cabotegravir and rilpivirine Injections at separate gluteus medius/ventrogluteal sites is expected to be recommended and generally will require administration in a clinic or possibly a pharmacy in a private space.

Delivery System Issues
• Cabenuva is expected to be approved for gluteal intramuscular use only. Cabotegravir and rilpivirine Injections at separate gluteus medius/ventrogluteal sites using the Z-track method is expected to be recommended and generally will require administration in a private space in a clinic or possibly a pharmacy.
• Clinics will need to assess available clinic space and develop staffing plans to accommodate more frequent office visits for some patients.
• State regulations or a clinic or institution’s internal policies may determine who can administer the injection. Nurses or other staff able to administer the injection may require training.
• More intensive patient reminder systems will likely be needed to ensure patients do not miss a monthly injection.
Healthcare Coverage
- Due to Cabenuva’s administration in a clinical setting, health insurers are likely to cover it as a medical benefit rather than a pharmacy benefit, which will affect how clinics obtain and bill for the medication.
- Patients’ out-of-pocket costs, and how they access co-pay assistance to help cover their out-of-pocket costs, also will be determined by how the medication is covered.
- Drugs covered under the health insurer’s medical benefit may require a flat co-insurance rate (e.g., 20% of the cost of the injections).
- For Medicare clients, Cabenuva is expected to be covered under Part B as a physician-administered drug, though some Medicare Advantage plans may opt to cover Cabenuva under Part D.
- Medicaid coverage policies will be determined on a state-by-state basis.

Procurement and Purchasing
- Drugs administered by a clinician, particularly those with cold-chain requirements, are generally not available through retail pharmacies. They are typically procured through one of the options below, and the method may be determined by the third-party payer.
  - Buy-and-bill: Provider or clinic purchases the drug/biologic product from a wholesaler or specialty distributor and bills the primary third-party payer. Provider or clinics assume liability for the cost of the drug under this model. Buy-and-bill is typical of drugs or biologics covered as a medical benefit.
  - White bagging: Provider submits prescription to specialty pharmacy; specialty pharmacy processes the claim and ships product to the provider for administration. White bagging may be typical of drugs or biologics covered as a pharmacy benefit. White bagging may also be an option for drugs or biologics covered as a medical benefit.
  - Brown bagging: Specialty pharmacy processes the claim and the patient picks it up and takes it to the provider for administration. Brown bagging is not expected to be an option for Cabenuva due to the special handling requirements.
- Temperature-controlled storage will be needed for Cabenuva.
- Separate buy-and-bill and white-bag inventories will need to be maintained. Cabenuva is expected to be available via buy-and-bill and white-bag mechanisms from a variety of specialty pharmacies and specialty distributors. The procurement mechanism will primarily depend on the client’s insurance coverage (i.e., whether Cabenuva is covered as a medical benefit or pharmacy benefit).

Ryan White HIV/AIDS Program Assistance
- Check with your state AIDS Drug Assistance Program regarding coverage of Cabenuva and the assistance that may be available. NASTAD maintains a directory of ADAP staff.
- The HIV/AIDS Bureau issued guidance in December 2019 recommending that AIDS Drug Assistance Programs add long-acting ARV products to their formularies when they become available. HAB also has determined that the costs of ARV product administration and/or office visits directly associated with provider administration of ARVs are allowable costs under the ADAP service category. In addition, ADAPs may cover medical co-payments associated with the administration of Cabenuva for patients with health insurance.
- Ryan White HIV/AIDS Programs may use the Outpatient/Ambulatory Health Services category to cover the costs associated Cabenuva administration where the Program is the primary payer of services (including where the state ADAP provides the medication); the Health Insurance Premium and Cost Sharing Assistance for Low-Income Individuals category may be used to cover any primary payer cost-sharing assistance requirements.

Cost-Sharing and Patient Assistance for the Uninsured
- Details on the cost sharing and patient assistance that will be available from ViiV Healthcare has not been released. This document will be updated when it comes available.

The information in this resource was compiled by the National Alliance of State and Territorial AIDS Directors and the HIV Medicine Association. Please email questions or comments to Tim Horn with NASTAD at thorn@nastad.org or Andrea Weddle with HIVMA at aweddle@hivma.org.